Cognyte Flat on EMEA Deal
Cognyte Software Ltd. (NASDAQ: CGNT) shares creep up Tuesday. The company, a global leader in software-driven technology for investigative analytics, today announced a deal for approximately $5 million with a law enforcement agency (LEA) in the Europe-Middle East-Africa (EMEA) region. With this initial contract, the LEA is deploying a suite of Cognyte solutions for greater innovation and automation – to enhance its operational effectiveness, accelerate investigations and drive stronger outcomes across critical cases.Confronted with complex criminal activity and increasingly sophisticated adversaries who exploit rapid advances in technology, the agency faced mounting pressure to deliver results quickly. It turned to Cognyte to equip its investigative units with advanced tools to turn growing volumes of data into fast, actionable insights. Cognyte’s platform enables analysts and field teams to identify, investigate and prevent criminal activity, delivering faster results and helping protect citizens and communities.“The customer turned to Cognyte to lead a significant upgrade of their investigative capabilities,” said Efi Nuri, Cognyte’s Chief Revenue Officer. “They needed proven technology that delivers clarity and drives real-world outcomes. Our ability to meet these urgent needs, both quickly and at scale, is fueling our growth and deepening our global impact. We look forward to building a trusted partnership and supporting their mission every step of the way.”CGNT shares advanced seven cents to $10.03.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


